196 related articles for article (PubMed ID: 22549158)
1. A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells.
Balch C; Naegeli K; Nam S; Ballard B; Hyslop A; Melki C; Reilly E; Hur MW; Nephew KP
Cancer Biol Ther; 2012 Jun; 13(8):681-93. PubMed ID: 22549158
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism.
Yang YL; Huang PH; Chiu HC; Kulp SK; Chen CS; Kuo CJ; Chen HD; Chen CS
Biochem Biophys Res Commun; 2013 May; 435(1):107-12. PubMed ID: 23624506
[TBL] [Abstract][Full Text] [Related]
3. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
[TBL] [Abstract][Full Text] [Related]
5. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
Yang YT; Balch C; Kulp SK; Mand MR; Nephew KP; Chen CS
Neoplasia; 2009 Jun; 11(6):552-63, 3 p following 563. PubMed ID: 19484144
[TBL] [Abstract][Full Text] [Related]
6. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
7. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
8. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
9. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
Bao L; Diao H; Dong N; Su X; Wang B; Mo Q; Yu H; Wang X; Chen C
Cell Biol Toxicol; 2016 Dec; 32(6):469-482. PubMed ID: 27423454
[TBL] [Abstract][Full Text] [Related]
11. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
12. Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 signaling pathway.
Xu LX; Li ZH; Tao YF; Li RH; Fang F; Zhao H; Li G; Li YH; Wang J; Feng X; Pan J
J Exp Clin Cancer Res; 2014 Dec; 33(1):108. PubMed ID: 25523932
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression and regulation in human ovarian carcinoma cells by luteinizing hormone.
Cui J; Eldredge JB; Xu Y; Puett D
PLoS One; 2011; 6(7):e21730. PubMed ID: 21765906
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
[TBL] [Abstract][Full Text] [Related]
15. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
[TBL] [Abstract][Full Text] [Related]
17. Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Taylor MD; Liu Y; Nagji AS; Theodosakis N; Jones DR
J Thorac Cardiovasc Surg; 2010 May; 139(5):1224-32, 1232.e1. PubMed ID: 20412959
[TBL] [Abstract][Full Text] [Related]
18. Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer.
Chen X; Stoeck A; Lee SJ; Shih IeM; Wang MM; Wang TL
Oncotarget; 2010 Jul; 1(3):210-8. PubMed ID: 20953350
[TBL] [Abstract][Full Text] [Related]
19. Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors.
Rodrigues Moita AJ; Bandolik JJ; Hansen FK; Kurz T; Hamacher A; Kassack MU
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167494
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]